title: Tiagabine appears not to be efficacious in the treatment of acute mania.
abstract: BACKGROUND
  Because a GABAergic hypofunction has been implied in the pathophysiology of mania, we have tested the antimanic properties of the GABA transporter 1 inhibitor tiagabine.
  
  
  METHODS
  An open trial was conducted in 8 acutely manic inpatients with DSM-IV bipolar I disorder, 2 of them with tiagabine monotherapy and 6 with tiagabine as an add-on to previously insufficient mood-stabilizing medication. The study duration was 14 days. Changes in psychopathology were assessed by the Bech-Rafaelsen Mania Rating Scale.
  
  
  RESULTS
  None of the patients showed clear-cut relief from manic symptoms during the 2-week observation period. In 2 patients, we saw pronounced side effects (nausea and vomiting in one and a generalized tonic-clonic seizure in the other).
  
  
  CONCLUSIONS
  The results from this open trial suggest that tiagabine seems to have no pronounced antimanic efficacy compared with standard treatments such as valproate, lithium, or neuroleptics. It also appears that rapid dosage increases for antimanic treatment can cause potentially severe side effects.
authors.affiliation: Department of Psychiatry, University of Munich, Germany. grunze@psy.med.uni-muenchen.de
authors.forename: H
authors.initials: H
authors.lastname: Grunze
authors.forename: A
authors.initials: A
authors.lastname: Erfurth
authors.forename: A
authors.initials: A
authors.lastname: Marcuse
authors.forename: B
authors.initials: B
authors.lastname: Amann
authors.forename: C
authors.initials: C
authors.lastname: Normann
authors.forename: J
authors.initials: J
authors.lastname: Walden
mesh_terms: D000208:Acute Disease; D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000175:diagnosis / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D018756:GABA Antagonists / Q000627:therapeutic use; D006760:Hospitalization; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009557:Nipecotic Acids / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D018967:Risperidone / Q000627:therapeutic use; D000078308:Tiagabine; D016896:Treatment Outcome; D014635:Valproic Acid / Q000627:therapeutic use
chemical_list: D000927:Anticonvulsants; D018756:GABA Antagonists; D009557:Nipecotic Acids; D014635:Valproic Acid; D008094:Lithium; D018967:Risperidone; D000078308:Tiagabine